Abdominal wall

Olympus Launches New Gynecology Contained Extraction System for Manual Tissue Morcellation

Retrieved on: 
Wednesday, September 14, 2022
Laparoscopy, Olympus, Bleeding, Endoscopy, Abdominal cavity, Hematoma, ASC, Superior, Partnership, Infection, Patient, Technology, Quality of life, Abdominal wall, Cell, Peritonitis, Integration, Surgeon, Method, Percussion section, Multimedia, Pneumoperitoneum, View, Medicine, Morcellator, Dentistry, Medical device, Security printing

CENTER VALLEY, Pa., Sept. 14, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the market launch of the Guardenia™ Contained Extraction System. Guardenia is the latest innovation in their contained tissue extraction product portfolio for gynecological procedures and is manufactured by Advanced Surgical Concepts (ASC) Ltd. of Bray, Ireland. Olympus America Inc. is the exclusive U.S. distributor of the system, which is indicated to contain and isolate tissue during, or prior to, surgical removal and/or extracorporeal manual morcellation.

Key Points: 
  • Guardenia is the latest innovation in their contained tissue extraction product portfolio for gynecological procedures and is manufactured by Advanced Surgical Concepts (ASC) Ltd. of Bray, Ireland.
  • Olympus America Inc. is the exclusive U.S. distributor of the system, which is indicated to contain and isolate tissue during, or prior to, surgical removal and/or extracorporeal manual morcellation.
  • The Guardenia system is designed to prevent the escape of cells into the abdominal cavity during extracorporeal manual morcellation, and its integrated guard provides protection against inadvertent damage from sharp surgical instruments around the incision.
  • Guardenia maximizes the amount of available space in the incision during a procedure by encroaching less into the incision and maintaining a stable protective area to complete manual tissue morcellation.

Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022

Retrieved on: 
Monday, September 12, 2022
People, Adenoid cystic carcinoma, Safety, Quality of life, Patient, Physician, Oncology, Abdominal wall, Nasdaq, Multiple myeloma, PR, ESMO, Aggressive fibromatosis, Treatment, ACC, Head, Organ dysfunction, European Society for Medical Oncology, RECIST, Pivotal, Plantar fibromatosis, FDA, T-Cell Acute Lymphoblastic Leukemia, Neoplasm, MM, AYLA, DOR, Royal Marsden Hospital, QOL, Progression-free survival, GLOBE, Congress, Therapy, Incidence, Doctor of Philosophy, MRI, Cancer, ORR, T-ALL, PFS, Chronic pain, Recurrence, Pharmaceutical industry, Medical imaging, Public relations, Notch, Part

The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.

Key Points: 
  • The data are being featured in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022.
  • The results presented today give us increased confidence in the potential for AL102 to improve the lives of patients with desmoid tumors.
  • For more information on the RINGSIDE Phase 2/3 study with AL102 for the treatment of desmoid tumors, please visit ClinicalTrials.gov and reference Identifier NCT04871282 ( RINGSIDE ).
  • AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors ( RINGSIDE ).

TELA Bio Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs; Data to Be Presented at 2022 American Hernia Society (AHS) Meeting

Retrieved on: 
Thursday, August 4, 2022
Diabetes, Medicine, Coronary artery disease, BRAVO, Private Securities Litigation Reform Act, Security (finance), SSO, Annual report, Rebar, Hernia, Recurrence, Quality of life, COPD, Foreign Bodies, AHS, Anatomy, 1S, Risk, Use, Patient, Company, Obesity, U.S. Securities and Exchange Commission, Surgical mesh, Sheep, Journal, Research, Solution, Health, Weakness, GLOBE, CEO, CDC, Surgeon, Abdominal wall, Inguinal hernia surgery, IceWall SSO, NASDAQ, Pharmaceutical industry, Medical imaging

MALVERN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that two studies examining clinical outcomes with use of its OviTex Reinforced Tissue Matrix will be presented at the 2022 American Hernia Society (AHS) Meeting.

Key Points: 
  • The conference, taking place from September 14-16, 2022, in Charlotte, North Carolina, will highlight the outcomes of two studies that underscore the efficacy of OviTex.
  • OviTex 1S Permanent demonstrated a 2.6% recurrence rate in ventral hernias repaired using open, laparoscopic, or robotic techniques at the 24-month time point.
  • These BRAVO 24-Month results follow the publication of the BRAVO 12-Month study, released in November 2021 in the Journal of Clinical Medicine .
  • OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists.

Dr. Joshua Tierney, MD, Commended for His Dedication to Patient Care Before and After Surgical Procedures

Retrieved on: 
Monday, April 4, 2022
Pancreas, Emergency, Stomach, List of Hindawi academic journals, Abdominal wall, Hernia, HPB, General surgery, Gallbladder, Cancer, Neoplasm, Patient, MD, Health, Technology, Hope, ERCP, Fellow, Chronic pancreatitis, Bile, Trauma, Wilms' tumor, Whipple, Medical device, Dentistry, Surveying, Medical imaging, Nebraska Panhandle

Today, Dr. Joshua Tierney was commended for his dedication to patient care before and after surgical procedures.

Key Points: 
  • Today, Dr. Joshua Tierney was commended for his dedication to patient care before and after surgical procedures.
  • Peers and patients alike consider Dr. Joshua Tierney to be one of the leading Whipple procedure surgeons, robotic hernia surgeons & robotic pancreatic surgeons in the country.
  • A surgeon isnt just somebody patients entrust with their procedure, and its also somebody they count on to provide comfort, care and support.
  • Learn more about Dr. Joshua Tierney, the conditions he treats and the surgical procedures he provides via the website: https://www.drjoshuatierney.com/

CHOP Announces Dollar-For-Dollar Matching Gift Campaign, Will Fund New Discoveries to Transform Personalized Pediatric Surgical Care

Retrieved on: 
Tuesday, February 8, 2022
Research, Parent, Prussia, Abdominal wall, Philadelphia, Liver, CHOP, TWINS, Hospital, Abdomen, Joe Altobelli, Children's Hospital of Philadelphia, Health, Diaphragm, Hope, Altobelli, Lilium, Medicine

From now until Valentines Day, February 14, the donor will match dollar-for-dollar every donation up to $2 million.

Key Points: 
  • From now until Valentines Day, February 14, the donor will match dollar-for-dollar every donation up to $2 million.
  • "The donations from this campaign will accelerate new discoveries and transform pediatric surgical care to ensure the best possible outcomes for children."
  • After nearly a year in intensive care at CHOP, the now separated twins are home in Chicago, where they are currently receiving follow up care and continue to reach developmental milestones.
  • About Children's Hospital of Philadelphia:A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital.

NYU Langone Appoints Director of Newly Established Abdominal Core Health Center

Retrieved on: 
Tuesday, December 14, 2021
Method, FACS, Treasurer, Education, Board, Master of Science, Federal University of the State of Rio de Janeiro, Doctor of Philosophy, ACH, Abdominal wall, NYU Langone Health, National university, Alma mater, Research, Hernia, NYU, Patient, Rio, Disease, Knowledge, Department, NYU Langone Hospital — Long Island, Surgeon, Faculty, Federal University of Rio de Janeiro, University, Albert Einstein College of Medicine, Montefiore Medical Center, Hospital, Medicine, Dentistry, Science, MD

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Flavio Malcher, MD, MSc, FACS, a renowned leader in the field of abdominal wall surgery and hernia repair, has joined NYU Langone Health as the Director of the newly created Abdominal Core Health Center.

Key Points: 
  • NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Flavio Malcher, MD, MSc, FACS, a renowned leader in the field of abdominal wall surgery and hernia repair, has joined NYU Langone Health as the Director of the newly created Abdominal Core Health Center.
  • Prior to joining NYU Langone, Malcher served as Director of the Abdominal Wall Program at Montefiore Medical Center where he was an assistant professor of surgery at the Albert Einstein College of Medicine.
  • At NYU Langone, Malcher will build a state-of-the-art Abdominal Core Health (ACH) Center to better serve patients with abdominal core conditions and help further the field of hernia repair.
  • "His experience and expertise will allow NYU Langone Health to move further into sub-specialized care and strengthen our abilities to provide world-class care to patients with complex abdominal core conditions."

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

Retrieved on: 
Friday, November 12, 2021
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Solar cycle 4, SITC, CXCL3, Cancer, Biopsy, Partial, CXCL8, Private Securities Litigation Reform Act, Form 10-K, Observation, Solar cycle 18, Neoplasm, PSA, Cytokine, Therapeutic index, Prostate cancer, Clinical trial, MCRPC, Abdominal wall, Security (finance), NASDAQ, CD8, Technology, Clinical Ovarian Cancer & Other Gynecologic Malignancies, RCC, Society, Trial of the century, Nivolumab, Serum, PD-1, Renal cell carcinoma, Forward-looking statement, CRPC, Annual report, Protein, U.S. Securities and Exchange Commission, IL-6, Large-cell lung carcinoma, Therapy, Degenerative disease, History, Pharmacodynamics, Prostate-specific antigen, Atrial fibrillation, Immunotherapy, Pancreas, IL-8, Patient, Melanoma, RECIST, Vaccine, Medical imaging, Pharmaceutical industry, Vudalimab (XmAb®717), Xencor, Inc., VUDALIMAB (XMAB®717), XENCOR, INC.

Dual targeting of these checkpoints through a bispecific antibody with a differentiated tolerability profile could meet an important unmet clinical need.

Key Points: 
  • Dual targeting of these checkpoints through a bispecific antibody with a differentiated tolerability profile could meet an important unmet clinical need.
  • We are now enrolling a Phase 2 study of vudalimab for patients with metastatic castration-resistant prostate cancer, as a monotherapy or in combination, depending on molecular subtype.
  • Baseline serum levels of the cytokines IL-6, IL-8 and IL-10 trended lower in patients who achieved a response on study.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

TELA Bio Announces Publication of 12-Month Results from the BRAVO Study with Continued Positive Outcomes Through 24 months

Retrieved on: 
Tuesday, November 9, 2021
Population, Quality of life, Maintenance, Private Securities Litigation Reform Act, Recurrence, Abdominal wall, Security (finance), NASDAQ, CEO, Weakness, Matrix, Use, COVID-19, General surgery, Research, PRS, Annual report, BRAVO, Risk, U.S. Securities and Exchange Commission, Medicine, Hernia, GLOBE, Surgical mesh, Journal, FACS, St. Francis Hospital, Sheep, Marketing, Patient, Medical imaging, Pharmaceutical industry

Final analysis is underway, and the 24-month BRAVO study results will be presented in a future peer-reviewed publication.

Key Points: 
  • Final analysis is underway, and the 24-month BRAVO study results will be presented in a future peer-reviewed publication.
  • "On behalf of the entire investigator team, we are pleased to see the 12-month clinical data of the BRAVO study in publication.
  • In addition to primary surgical outcomes, patient quality of life was also assessed as part of the BRAVO study.
  • "This initial publication of the BRAVO study represents an important checkpoint for TELA Bio's corporate mission.

Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors

Retrieved on: 
Thursday, September 23, 2021
People, T-Cell Acute Lymphoblastic Leukemia, Recurrence, ACC, Private Securities Litigation Reform Act, Quality, Growth, Safety, Aggressive fibromatosis, Adenoid cystic carcinoma, SEC, Confidentiality, T-ALL, PR, U.S. Securities and Exchange Commission, TNBC, Abdominal wall, Adult, Incidence, BMS, Organ dysfunction, PFS, Clinical trial, Current Oncology, Neoplasm, Annual report, Therapy, AYLA, NASDAQ, Plantar fibromatosis, FDA, Cancer, Multiple myeloma, ORR, MM, QOL, GLOBE, Chronic pain, MRI, Novartis, Risk, Doctor of Philosophy, Patient, Adolescence, Ownership, Head, Pivotal, COVID-19, DOR, Research, Quality of life, Pharmaceutical industry, Medical imaging

This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.

Key Points: 
  • This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.
  • The data included in the case study are based on earlier Phase 1 results and compassionate use of AL101 in desmoid tumors.
  • Both of these patients case studies represent additional evidence to support the development of our gamma secretase inhibitor, AL102 for the treatment of desmoid tumors.
  • The body of data conducted by BMS in patients with desmoid tumors implicating the role of gamma secretase inhibition furthers our hypothesis for treating desmoid tumors through AL102s mechanism of action, said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala.

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

Retrieved on: 
Monday, September 13, 2021
Inguinal hernia surgery, Society of American Gastrointestinal and Endoscopic Surgeons, Surgical mesh, U.S. Securities and Exchange Commission, Weakness, DO, Security (finance), Private Securities Litigation Reform Act, DRS, Medical research, Rebar, Marketing, Patient, Society, St. Francis Hospital, Use, Foreign body, Annual report, NASDAQ, Hernia, COVID-19, General surgery, MBA, Matrix, Sheep, GLOBE, Robot-assisted surgery, FACS, Recurrence, Risk, Goal, Journal, PRS, Maintenance, Abdominal wall, Medical imaging, Medical device

Two poster presentations revealed new data, while a third video presentation demonstrated a novel surgical technique that leverages the unique properties of OviTex Reinforced Tissue Matrix .

Key Points: 
  • Two poster presentations revealed new data, while a third video presentation demonstrated a novel surgical technique that leverages the unique properties of OviTex Reinforced Tissue Matrix .
  • Dr. Szotek stated, "The Reinforced Biologic Augmented Repair, or the ReBAR technique, applies sound hernia surgery principles while leveraging the benefits of a reinforced biologic material with a low synthetic foreign body burden.
  • Our initial goals in adopting OviTex were to lower recurrences while decreasing the amount of synthetic foreign body implanted.
  • Szotek and Banaschak employing the ReBAR technique was recently highlighted in an article entitled, Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair (ReBAR) published in the Journal of Clinical and Medical Research.